Due to having high TMB, BRCA1/2 germline mutation related tumors are considered to be candidates for immune checkpoint inhibition strategies, which were successful in highly mutated melanoma and lung cancers [8]. This evidence concerns the gene BRCA1 and lung carcinoma.